Klotho: Mechanisms, Physiological Roles, and Therapeutic Potential

Disclaimer: All articles and product details provided on this website are intended for educational and informational purposes only. The products listed here are for in-vitro research only. In-vitro studies are conducted outside of living organisms. These products are not intended as medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease. The direct or indirect administration of these substances to humans or animals is unequivocally prohibited under applicable law.

Introduction

Klotho is a protein that has become a central focus in aging and chronic disease research. Discovered in 1997 and named after the Greek goddess of fate, it has been linked to longevity, metabolic regulation, and multiple disease pathways. Studies since its identification have revealed broad physiological functions and potential therapeutic applications.

Discovery and Genetic Context

The Klotho gene was first described by Kuro-o and colleagues in 1997 during investigations of genetic determinants of lifespan in mice. Loss-of-function mutations in the Klotho gene (klotho−/−) led to features resembling premature aging, such as vascular calcification, osteoporosis, dermal atrophy, and early death. Conversely, animals with elevated Klotho expression demonstrated increased survival. In humans, the gene is located on chromosome 13q12 and encodes a type I transmembrane protein, most abundantly expressed in the kidneys, brain, and endocrine tissues.

Molecular Structure and Isoforms

Klotho exists in two major forms: a membrane-bound variant and a soluble circulating variant. The membrane form functions as a co-receptor for fibroblast growth factor 23 (FGF23). Soluble Klotho, generated by enzymatic cleavage or alternative splicing, is detectable in blood, cerebrospinal fluid, and urine. Soluble Klotho can circulate as full-length protein or shorter fragments (KL1 and KL2).

Function as a Co-Receptor for FGF23

Membrane-bound Klotho forms a complex with FGF23 and its receptor FGFR1c, enhancing phosphate regulation. FGF23, secreted by osteoblasts and osteocytes, reduces renal phosphate reabsorption and decreases the synthesis of active vitamin D (1,25-dihydroxyvitamin D3). Klotho is required for efficient binding and signaling, making it essential for phosphate metabolism.

Regulation of Phosphate Balance

Phosphate is crucial for skeletal integrity, cellular signaling, and energy metabolism. The FGF23-Klotho system maintains phosphate homeostasis through multiple mechanisms. In the kidneys, this axis reduces expression of sodium-phosphate co-transporters (NaPi-2a, NaPi-2c), promoting phosphate excretion. Additionally, it suppresses 1α-hydroxylase activity, thereby limiting vitamin D activation and reducing intestinal phosphate absorption.

Association with Aging

Klotho has been closely linked to biological aging. Mice lacking Klotho display features such as vascular stiffness, reduced bone density, cognitive decline, and shortened lifespan. Overexpression, however, extends survival and reduces age-related pathologies. The mechanisms involve reduction of oxidative stress, suppression of inflammatory signaling, and attenuation of cellular senescence.

Klotho upregulates antioxidant defenses such as superoxide dismutase and reduces reactive oxygen species. It also interferes with NF-κB–mediated inflammatory signaling, decreasing pro-inflammatory cytokine production. These actions contribute to its role as a systemic protector against age-associated decline.

Influence on Cellular Senescence

Klotho is involved in maintaining telomere stability and regulating insulin/IGF-1 signaling. It enhances telomerase activity, preserving genomic integrity, and modulates IGF-1 signaling pathways, which are associated with extended lifespan and reduced cellular senescence.

Role in Chronic Kidney Disease

Chronic kidney disease (CKD) is characterized by progressive loss of renal function and a marked decline in circulating Klotho levels. Reduced Klotho expression disrupts phosphate balance, accelerates vascular calcification, and increases cardiovascular morbidity. This deficiency worsens hyperphosphatemia and destabilizes the FGF23-Klotho system, contributing to poor outcomes in CKD patients.

Therapeutic Strategies Targeting Klotho

Gene Therapy

Delivery of the Klotho gene to restore expression has been tested in preclinical studies. These interventions improved renal function and mitigated premature aging features in animal models. While promising, clinical translation requires refinement in gene delivery systems and long-term safety evaluation.

Recombinant Protein Administration

Exogenous administration of soluble recombinant Klotho protein has shown protective effects in experimental models. Benefits include reduction of renal injury, mitigation of oxidative stress, and improved cardiovascular outcomes. Human clinical trials are required to confirm its therapeutic safety and effectiveness.

Small Molecule Modulators

Another approach involves identifying compounds that enhance endogenous Klotho expression or mimic its function. High-throughput screening has identified small molecules capable of increasing Klotho activity, offering potential for more accessible therapeutic options.

Neuroprotective Actions

Klotho is expressed in the brain, particularly in the choroid plexus, and its levels decline with age. Low Klotho expression has been associated with impaired cognition and increased susceptibility to neurodegenerative disease. Experimental studies suggest Klotho modulates glutamate signaling, enhances synaptic plasticity, and reduces oxidative burden in neural tissue. These findings point toward potential applications in disorders such as Alzheimer’s disease.

Challenges and Future Directions

Although the therapeutic promise of Klotho is considerable, key obstacles remain. A deeper understanding of its molecular signaling pathways is needed. Furthermore, optimization of delivery methods, tissue-specific targeting, and long-term safety studies will be critical for translation into clinical medicine.

Conclusion

Klotho is a multifunctional protein that influences phosphate balance, oxidative stress, inflammation, and aging. Its deficiency contributes to CKD progression and age-related disease, while its supplementation or upregulation shows therapeutic promise. Ongoing research into Klotho’s molecular pathways and its clinical applications may open new strategies for improving longevity and managing chronic disease.

REFERENCES

1. Navarro-García, J.A., Salguero-Bodes, R., González-Lafuente, L. et al. The anti-aging factor Klotho protects against acquired long QT syndrome induced by uremia and promoted by fibroblast growth factor 23. BMC Med 20, 14 (2022). https://doi.org/10.1186/s12916-021-02209-9
2. Kuro-o, M., Matsumura, Y., Aizawa, H. et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390, 45–51 (1997). https://doi.org/10.1038/36285
3. Prud’homme, Gérald J., et al. “Pathobiology of the Klotho Antiaging Protein and Therapeutic Considerations.” Frontiers in Aging, vol. 3, 12 July 2022, https://doi.org/10.3389/fragi.2022.931331. 
4. Kuro-o, M. Klotho, phosphate and FGF-23 in ageing and disturbed mineral metabolism. Nat Rev Nephrol 9, 650–660 (2013). https://doi.org/10.1038/nrneph.2013.111